news, journals and articles from all over the world.
In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer
Read moreNew findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for
Read moreBethesda, MD (Dec. 6, 2019) — Gastric intestinal metaplasia (GIM), which is linked to non-cardia gastric cancer, is often detected
Read moreRecommendations define how and when radiation therapy should be used to treat the most common types of skin cancer
Read moreHollings Cancer Center researchers explore how to help the 60 percent of patients with TNBC who do not respond well to more traditional treatments
Read moreMayo Clinic researchers will present findings at the American Society of Hematology Annual Meeting Dec. 7–10 in Orlando.
New Mayo Clinic studies to be presented include:
DNA analysis identifies elevated risk factor for myeloma in individuals of African ancestry
Study identifies more precise assessment measures for patients newly diagnosed with chronic lymphocytic leukemia
Researchers develop method to assess cancer-fighting cell therapy’s effectiveness
UT Southwestern researchers have developed a software tool that uses artificial intelligence to recognize cancer cells from digital pathology images – giving clinicians a powerful way of predicting patient outcomes.
Read more
A new study by Yale Cancer Center (YCC) researchers shows understanding treatment patterns for patients with acute myeloid leukemia (AML) is vital to develop strategies to improve outcomes.
Read more
A new study by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.
Read more
A new study from scientists at UCLA helps explain why some people with advanced cancer may not respond to one of the leading immunotherapies, PD-1 blockade, and how a new combination approach may help overcome resistance to the immunotherapy drug.
Read moreBelow please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine
Read moreOrlando FL. – December 9, 2019 – Scientists will present more than 40 abstracts highlighting research driven in part by
Read more